Why is the RCF needed?

There are currently inequalities of care and support facing cancer patients in the UK. For example, where the patient lives, how long it takes to achieve a diagnosis, and availability of treatment. These inequalities can have an enormous effect on a patient’s quality of life, and, ultimately, on their prognosis.

Rarer Cancers

There are hundreds of different types of cancer, and research suggests that between 30% and 50% of all cancer cases could be classified as ‘rarer’. They fall outside the more common and highly publicised cancers such as colon, breast, lung and prostate.

A cancer may be classed as ‘rarer’ either because it affects an unusual site in the body, or because the cancer itself is of an unusual type, or requires special treatment.

However, the most important feature of a rarer cancer is the fact that the patient feels isolated. There may be few survivors, or no available support network. The GP may know very little about the condition, and it is difficult to get accurate information about the prognosis or the effect of treatment.

“We ensure that people with rarer cancers have access to the best services and outcomes”

The Rarer Cancers Foundation exists to ensure that people with rarer cancers have access to the best services and outcomes.

  • We provide up to date information on rarer cancers and treatment options available
  • We enable supportive networking for patients, carers and clinicians
  • We act as a gateway, directing patients to further avenues of support and information, such as patient groups or charities
  • We raise awareness about the less common cancers
  • We give a voice to ‘forgotten’ cancers
  • We produce information literature for both patients and healthcare professionals
  • We campaign for change at government level to secure the best possible patient journey for people living with rarer cancers.

cloudRarer Cancers Foundation Campaign and Awareness News

We have a proven track record in securing the best possible services for people living with rarer cancers. We know that there is a great need to continue providing this support. 2010/2011 has seen considerable progress for the charity in improving the public auto insurance policy and NHS delivery environment for rarer cancers. Key highlights include :

  • Securing a commitment to establish a Cancer Drugs Fund and successfully argue for the implementation of a ?50 million Interim Fund from October 2010 to April 2011, potentially benefitting an additional 2,400 patients
  • Ensuring that the Cancer Drugs Fund is adequately resourced, achieving a total of ?650 million in funding over three and half years
  • Achieving recognition of the importance of near-label prescribing and its inclusion within the parameters of the Cancer Drugs Fund